Cargando…
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients
Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. Since the underly...
Autores principales: | Colom-Fernández, Beatriz, Kreutzman, Anna, Marcos-Jiménez, Ana, García-Gutiérrez, Valentín, Cuesta-Mateos, Carlos, Portero-Sainz, Itxaso, Pérez-García, Yaiza, Casado, Luis Felipe, Sánchez-Guijo, Fermín, Martínez-López, Joaquín, Ayala, Rosa M., Boqué, Concha, Xicoy, Blanca, Montero, Isabel, Soto, César, Paz, Raquel, Silva, Gabriela, Vega-Piris, Lorena, Steegmann, Juan Luis, Muñoz-Calleja, Cecilia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886582/ https://www.ncbi.nlm.nih.gov/pubmed/31824308 http://dx.doi.org/10.3389/fphar.2019.01340 |
Ejemplares similares
-
Dasatinib-induced spleen contraction leads to transient lymphocytosis
por: Marcos-Jiménez, Ana, et al.
Publicado: (2022) -
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016) -
Glucocorticoid-induced redistribution lymphocytosis in mantle cell lymphoma with hyaline vascular Castleman disease-like features
por: Togitani, Kazuto, et al.
Publicado: (2021) -
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
por: Kreutzman, Anna, et al.
Publicado: (2014) -
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
por: Garcia-Gomez, Antonio, et al.
Publicado: (2012)